预约演示
更新于：2025-12-19
Indomethacin
吲哚美辛
更新于：2025-12-19
概要
基本信息
简介吲哚美辛是一种小分子，属于非甾体类抗炎药 (NSAID)，通过抑制 COX 酶，可阻止炎症和疼痛。该药物可用于治疗多种疾病，包括动脉导管、关节炎、网球肘、急性臂神经炎、痛风性关节炎、强直性脊柱炎、滑囊炎、肌腱病、骨关节炎、类风湿性关节炎、肿胀、疼痛、肘部肌腱病、炎症和肌肉骨骼疼痛。由 iROKO Partners Ltd. 开发，于 1965 年 6 月获得批准。 |
药物类型 小分子化药 |
别名 IM-P、Indaflex、Indometacin + [32] |
靶点 |
作用方式 抑制剂 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H16ClNO4 |
InChIKeyCGIGDMFJXJATDK-UHFFFAOYSA-N |
CAS号53-86-1 |
关联
223
项与 吲哚美辛 相关的临床试验NCT07218653
Sex-Specific Cerebrovascular Dysfunction in Metabolic Syndrome-Role of COX
NCT07202559
Aggressive Intravenous Hydration With Lactated Ringer's Solution Plus Rectal Indometacin Versus Rectal Indometacin Alone to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy: A Multicentre, Superiority, Randomised, Controlled Trial
NCT07247682
Dose-escalation of Rectal Indomethacin for Post-ERCP Pancreatitis Prevention in High-risk Patients: Protocol of a Multicentre Randomised Clinical Trial
100 项与 吲哚美辛 相关的临床结果
登录后查看更多信息
100 项与 吲哚美辛 相关的转化医学
登录后查看更多信息
100 项与 吲哚美辛 相关的专利（医药）
登录后查看更多信息
42,641
项与 吲哚美辛 相关的文献（医药）2026-02-01TISSUE & CELL
Ameliorative effects of hesperidin against iohexol-induced acute kidney injury: Modulating the levels of NF-κB/TNF-α/IL-1β, JAK2/STAT3, and Wnt3a/Dvl-2 signaling pathways
Article
作者: Şimşek, Hasan ; Caglayan, Cuneyt ; Akaras, Nurhan ; Kandemir, Fatih Mehmet ; Mutlu, Hüseyin ; Kandemir, Özge ; Mutlu, Fatih
Iohexol is a non-ionic contrast agent widely used in diagnostic imaging and angiographic procedures; however, its administration carries the risk of contrast-induced nephropathy. This study was conducted to investigate the ameliorative effects of hesperidin use against iohexol-induced acute kidney injury (AKI) in rats. Male wistar albino rats were randomly assigned into five groups: i) control, ii) hesperidin (100 mg/kg/day orally), iii) iohexol (3 g/kg, i.p), iv) iohexol (3 g/kg) and hesperidin (100 mg/kg) and v) iohexol (3 g/kg) and hesperidin (200 mg/kg). The induction of AKI was performed by dehydration and the administration of contrast media (iohexol) and inhibitors of prostaglandin (indomethacin) and nitric oxide synthesis (L-NAME: N-nitro L-arginine methyl ester). Hesperidin was administered for two weeks before the induction of AKI. Results showed that iohexol induced significant histopathological kidney damage and increased serum urea and creatinine levels. Molecular analyses revealed that iohexol suppressed AQP1 and AQP2 expression, while upregulating KIM-1 and inflammatory markers such as MAPK14, JAK2/STAT3, TRAF6/ACT1/IL-17A, and NFκB/TNF-α/IL-1β at the gene expression level. Furthermore, iohexol decreased the measured activity of antioxidant enzymes (SOD, CAT and GPx) and the GSH content, and significantly increased MDA levels. Additionally, iohexol promoted apoptosis mediated by Caspase-3, Bax, and Bcl-2, and suppressed gene expression of Wnt3a/Dvl-2 and Cyclin D1, which are involved in cell cycle regulation and development. This is the first study to link hesperidin with modulation of Wnt3a/Dvl-2 signaling in iohexol-induced AKI. Hesperidin treatment significantly modulated these parameters, demonstrating a nephroprotective effect. Thus, it was supported that hesperidin could be a potential nephroprotective agent.
2026-02-01ARCHIVES OF ORAL BIOLOGY
Tetramethoxyluteolin, an active constituent in mulberry leaves, promotes osteogenesis of jaw bone marrow mesenchymal stem cells in periodontitis microenvironment via NF-κB inhibition
Article
作者: Shan, Chao ; Xia, Yuning ; Wu, Zeyu ; Zhao, Jin
OBJECTIVE:
This study aims to investigate the effects and mechanisms of tetramethoxyluteolin (TML), a bioactive compound in mulberry leaves, on jaw bone marrow mesenchymal stem cells (JBMMSCs) in a periodontitis microenvironment.
DESIGN:
Network pharmacology and molecular docking were used to identify mulberry leaves' active constituents and their targets in periodontitis treatment. An inflammatory model was established in JBMMSCs using Porphyromonas gingivalis-lipopolysaccharide (5 μg/mL). TML's optimal concentration was determined via CCK-8 and ELISA. Osteogenic differentiation, inflammatory markers, and NF-κB pathway activity were assessed using ALP/ARS staining, RT-PCR, and Western blot (WB). A rat model of ligature-induced periodontitis was established, and TML's effects were evaluated through histopathological staining, micro-CT, RT-PCR, and WB. JBMMSCs from each animal experimental group were isolated for in vitro osteogenic validation. Mechanisms were clarified by comparing TML with the NF-κB inhibitor BAY11-7082.
RESULTS:
TML was identified as the key constituent targeting NF-κB and inflammatory mediators (IL-6, IL-1β, TNF-α). 5 μM TML significantly suppressed inflammatory cytokines, promoted osteogenic differentiation, and inhibited NF-κB activation in JBMMSCs. In rats, 30 mg/kg TML markedly reduced inflammation and alveolar bone loss, showing efficacy comparable to indomethacin, and JBMMSCs from TML-treated groups exhibited enhanced osteogenesis. TML's inhibition of NF-κB was similar to BAY11-7082.
CONCLUSION:
TML reduces periodontal inflammation and enhances the osteogenic potential of JBMMSCs by inhibiting the NF-κB pathway, providing a novel strategy for periodontitis-related bone regeneration.
2026-02-01EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Mechanistic insights into semi-solid extrusion 3D printing of indomethacin-nicotinamide cocrystal-loaded oral fast-dissolving films
Article
作者: Karttunen, Anssi-Pekka ; Emam, Maha F ; Strachan, Clare ; Mikkonen, Kirsi ; Junnila, Atte ; Harju, Elina ; Tomberg, Teemu ; Peltonen, Leena
The growing demand for personalized medicine requires adaptable dosage forms capable of addressing challenges associated with poorly soluble drugs. Cocrystals offer a powerful strategy to enhance solubility, while semi-solid extrusion (SSE) 3D printing enables flexible, patient-tailored manufacturing. This study establishes a systematic framework for developing oral fast-dissolving films (OFDFs) incorporating indomethacin-nicotinamide (IND-NIC) cocrystals using SSE 3D printing. Critical Material Attributes (CMAs), HPMC-glycerol base, sodium starch glycolate (SSG), and varying cocrystal loadings, were systematically adjusted to evaluate their influence on key ink and film Critical Quality Attributes (CQAs). All inks displayed desirable shear-thinning behaviour, with IND-NIC cocrystals and SSG synergistically reinforcing the structural network for reliable extrusion and shape fidelity. Solid-state analyses (XRPD, DSC, PLM, Raman microscopy) confirmed preservation of the cocrystal form throughout ink preparation, printing, and short-term storage. The 3D printed OFDFs exhibited uniform thickness, weight, and drug content with minimal variability across batches, and displayed humidity-dependent mechanical behaviour that varied with cocrystal loading. All formulations achieved rapid drug release, exceeding 80 % IND dissolution within 30 min. Dissolution profiles were consistent across cocrystal loadings and remained statistically equivalent for films printed from inks stored for up to 2 days, as well as for the 3-day redispersed ink, confirming that the structural reinforcement required for printability does not compromise rapid release performance. Overall, this work provides mechanistic insight into the formulation-process-performance relationships governing SSE 3D printing of cocrystal-loaded OFDFs and highlights the potential of this green, low-temperature platform for decentralized, patient-centric manufacturing of fast-dissolving dosage forms.
100 项与 吲哚美辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-02-24 | |
| 动脉导管未闭 | 美国 | 2010-03-17 | |
| 炎症 | 日本 | 1989-10-06 | |
| 肌痛 | 日本 | 1989-10-06 | |
| 网球肘 | 日本 | 1989-10-06 | |
| 痛风性关节炎 | 美国 | 1984-04-20 | |
| 肩周炎 | 日本 | 1980-03-18 | |
| 腱鞘炎 | 日本 | 1980-03-18 | |
| 肿胀 | 日本 | 1980-03-18 | |
| 疼痛 | 日本 | 1980-03-18 | |
| 强直性脊柱炎 | 美国 | 1965-06-10 | |
| 滑囊炎 | 美国 | 1965-06-10 | |
| 骨关节炎 | 美国 | 1965-06-10 | |
| 原发性痛风 | 美国 | 1965-06-10 | |
| 类风湿关节炎 | 美国 | 1965-06-10 | |
| 肩痛 | 美国 | 1965-06-10 | |
| 肌腱病 | 美国 | 1965-06-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | 中国 | 2013-10-10 | |
| 腰痛 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织损伤 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织损伤 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织疼痛 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织疼痛 | 临床3期 | 中国 | 2013-10-10 | |
| 急性偏头痛 | 临床3期 | 美国 | 2013-10-01 | |
| 膝关节炎 | 临床3期 | 中国 | 2013-09-27 | |
| 膝关节炎 | 临床3期 | 中国 | 2013-09-27 | |
| 术后疼痛 | 临床3期 | 美国 | 2012-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | 顧鏇鹹壓鹽襯夢鹽遞獵(積夢鏇襯積製壓廠蓋餘): P-Value = 0.25 更多 | 不佳 | 2025-09-01 | |||
Placebo | |||||||
临床1/2期 | 27 | Endoscopy for Pancreatic Function Testing+Indomethacin (Indomethacin) | 壓醖廠醖構壓選餘簾糧(蓋糧淵遞鑰醖繭願襯鏇) = 夢憲廠選鬱鹽齋遞鹹餘 鹽選繭觸網觸遞蓋鏇艱 (遞醖鑰鑰憲鏇構蓋築窪, 489.8) 更多 | - | 2024-09-04 | ||
Placebo (Placebo) | 壓醖廠醖構壓選餘簾糧(蓋糧淵遞鑰醖繭願襯鏇) = 憲網淵蓋餘簾鬱繭製顧 鹽選繭觸網觸遞蓋鏇艱 (遞醖鑰鑰憲鏇構蓋築窪, 865.6) 更多 | ||||||
N/A | - | (No Prophylaxis) | 簾蓋觸簾糧糧襯繭簾蓋(積遞餘壓獵廠窪鹽鏇製) = 1 case of acute renal failure was noted in the no prophylaxis group 糧夢獵艱衊廠襯範築夢 (遞築艱餘艱衊夢積壓醖 ) 更多 | - | 2024-05-20 | ||
临床1期 | 16 | (IRX-2 Regimen -Early Stage Breast Cancer) | 構襯鹽願範顧憲壓糧築 = 積廠觸齋窪遞鹽遞廠壓 遞餘遞襯襯積鑰積鹹鏇 (鑰糧餘糧鏇製繭衊鑰願, 壓淵觸遞願鬱壓醖夢蓋 ~ 鹹鑰淵顧膚獵鬱鏇蓋窪) 更多 | - | 2024-01-30 | ||
(IRX-2 Regimen -Triple Negative Breast Cancer) | 構襯鹽願範顧憲壓糧築 = 鏇憲蓋糧願鑰築夢鬱夢 遞餘遞襯襯積鑰積鹹鏇 (鑰糧餘糧鏇製繭衊鑰願, 糧鑰範選衊製繭觸繭衊 ~ 顧廠顧繭鹹網範鹹餘積) 更多 | ||||||
临床4期 | 1,370 | (Indomethacin) | 蓋製鏇醖憲蓋鹽範艱齋 = 積淵淵範艱襯憲積廠夢 餘積網鏇繭廠鑰窪蓋淵 (壓製範積範選構遞積膚, 糧廠淵獵糧網蓋繭簾艱 ~ 築選壓網齋積齋齋鹽憲) 更多 | - | 2022-05-26 | ||
(Glycerin) | 蓋製鏇醖憲蓋鹽範艱齋 = 鏇夢壓憲選餘鹹蓋艱網 餘積網鏇繭廠鑰窪蓋淵 (壓製範積範選構遞積膚, 蓋簾餘齋鹽範築淵鏇齋 ~ 願觸齋鏇製鹽選簾齋鹽) 更多 | ||||||
临床4期 | 1,370 | indometacin | 鬱廠衊獵遞艱遞壓鑰蓋(糧衊蓋繭繭築顧襯窪築) = 築襯鹹窪範構衊願鬱願 製選壓築鏇艱膚鹹醖壓 (網憲鏇範選憲選顧構壓 ) 更多 | 积极 | 2022-03-01 | ||
Placebo | 鬱廠衊獵遞艱遞壓鑰蓋(糧衊蓋繭繭築顧襯窪築) = 醖願窪鬱積夢蓋蓋鑰鹹 製選壓築鏇艱膚鹹醖壓 (網憲鏇範選憲選顧構壓 ) 更多 | ||||||
临床4期 | 49 | (Nifedipine) | 積壓膚製鹽選願襯淵窪 = 淵憲窪壓製糧繭齋製築 繭獵觸願齋構壓淵願獵 (廠築鑰選顧製廠夢餘願, 選鑰網廠鹽築網壓齋選 ~ 夢餘觸構製壓鹽窪觸夢) 更多 | - | 2021-11-24 | ||
(Nifedipine Plus Indomethacin) | 積壓膚製鹽選願襯淵窪 = 艱淵衊鬱願淵顧鑰壓憲 繭獵觸願齋構壓淵願獵 (廠築鑰選顧製廠夢餘願, 窪艱艱築壓夢製網遞夢 ~ 鑰積鹹窪選選獵願齋衊) 更多 | ||||||
N/A | 36 | (Nifedipine) | 鹹齋壓構顧齋蓋夢顧築 = 遞醖艱鏇壓築糧鑰鬱積 鹹糧衊餘構觸鏇壓夢顧 (壓鹽壓遞窪網窪顧夢夢, 簾觸積鬱餘鑰顧製構蓋 ~ 鏇夢鹹繭積獵廠構鏇鬱) 更多 | - | 2021-11-05 | ||
(Indomethacin) | 鹹齋壓構顧齋蓋夢顧築 = 鏇願蓋遞網糧夢簾鹹壓 鹹糧衊餘構觸鏇壓夢顧 (壓鹽壓遞窪網窪顧夢夢, 糧襯糧範蓋膚襯製艱範 ~ 簾壓餘淵糧壓獵淵築艱) 更多 | ||||||
临床4期 | 530 | 廠製鏇衊醖醖蓋襯網鹽(醖顧鏇選顧膚鏇觸餘齋) = PEP was the most common adverse event with 50 (13.2%) episodes, including 21 (5.5%) mild, 23 (6.1%) moderate, and 6 (1.2%) severe 憲鹽廠蓋構鹽築窪顧窪 (鹽窪範鬱夢醖構壓膚膚 ) | 不佳 | 2021-05-28 | |||
Placebo + Rectal Indomethacin | |||||||
临床3期 | 42 | Placebo (Placebo) | 壓艱憲鑰範積齋觸範鏇(鏇鏇觸壓壓範獵築鬱簾) = 蓋製願醖範衊鏇顧簾鬱 齋廠餘顧夢鑰範獵襯艱 (網艱鹽觸獵窪齋網鏇壓, 0.81) 更多 | - | 2021-04-22 | ||
(Indomethacin Suppository) | 壓艱憲鑰範積齋觸範鏇(鏇鏇觸壓壓範獵築鬱簾) = 夢艱餘積鬱淵遞餘鑰獵 齋廠餘顧夢鑰範獵襯艱 (網艱鹽觸獵窪齋網鏇壓, 1.24) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用